A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia

Inclusion Criteria:

• Clinical and definitive histologic diagnosis of WM.

• Meeting ≥ 1 criterion for treatment according to consensus panel criteria from the 2nd International Workshop on Waldenström's Macroglobulinemia (IWWM).

• For Cohorts 1-3, refractory or relapsed disease at study entry unless participantshad intolerance to the most recent therapy. Refractory disease is defined as notattaining at least a major response, or progressing while on or within 6 months ofcompleting therapy. Relapsed disease is defined as attaining at least a majorresponse to therapy and meeting the criteria for disease progression beyond 6 monthsafter completing therapy.

• For Cohort 4, patients must not have received prior therapy for WM (except forplasmapheresis).

• Adequate organ function.

Exclusion Criteria:

• Central nervous system (CNS) involvement by WM.

• Transformation to aggressive lymphoma, such as diffuse large B-cell lymphoma.

• History of other malignancies ≤ 2 years before study entry.

• Uncontrolled active systemic infection or recent infection requiring parenteralantimicrobial therapy that was completed ≤ 14 days before the first dose of thestudy drug.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.